Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

被引:111
作者
Pantoflickova, D [1 ]
Dorta, G
Ravic, M
Jornod, P
Blum, AL
机构
[1] CHU Vaudois, Dept Gastroenterol, CH-1012 Lausanne, Switzerland
[2] Eisai & Co Ltd, London, England
关键词
D O I
10.1046/j.1365-2036.2003.01496.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Rapid and consistent acid suppression on the first day of dosing may be important in treating acid-related disorders. Aim: To compare the antisecretory activity and onset of action of single doses of rabeprazole, lansoprazole, pantoprazole, omeprazole capsule, omeprazole multiple unit pellet system (MUPS) tablet and placebo in healthy Helicobacter pylori -negative subjects. Methods: This cross-over, double-blind, randomized study was performed in 18 H. pylori -negative subjects. Twenty-four-hour intragastric pH monitoring was performed on the day of treatment (once-daily dose of rabeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, omeprazole capsule 20 mg, omeprazole MUPS tablet 20 mg or placebo). Results: The intragastric pH (3.4) and time at pH > 4 during the 24 h post-dose (8.0 h) were significantly greater with rabeprazole than with lansoprazole, pantoprazole, omeprazole capsule, omeprazole MUPS tablet or placebo (P less than or equal to 0.04 for rabeprazole vs. the others). Daytime and night-time pH values were higher with rabeprazole and lansoprazole than with pantoprazole, omeprazole capsule and omeprazole MUPS tablet (P less than or equal to 0.04). Conclusion: Rabeprazole was the most potent acid inhibitor of all the proton pump inhibitors tested during the first day of dosing.
引用
收藏
页码:1507 / 1514
页数:8
相关论文
共 36 条
[1]   Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole [J].
Andersson, T ;
Hassan-Alin, M ;
Hasselgren, G ;
Röhss, K ;
Weidolf, L .
CLINICAL PHARMACOKINETICS, 2001, 40 (06) :411-426
[2]  
Baisley K, 2002, GUT, V50, pA63
[3]   Review article:: rabeprazole-based therapy in Helicobacter pylori eradication [J].
Barth, J ;
Hahne, W .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 :31-33
[4]   APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
BURGET, D ;
HOWDEN, CW ;
WILKINSON, J ;
HUNT, RH .
DIGESTION, 1992, 51 :59-67
[5]   DECREASED ORAL BIOAVAILABILITY OF LANSOPRAZOLE IN HEALTHY-VOLUNTEERS WHEN GIVEN WITH A STANDARDIZED BREAKFAST [J].
BERGSTRAND, R ;
GRIND, M ;
NYBERG, G ;
OLOFSSON, B .
CLINICAL DRUG INVESTIGATION, 1995, 9 (02) :67-71
[6]   Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents [J].
Besancon, M ;
Simon, A ;
Sachs, G ;
Shin, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (36) :22438-22446
[7]   Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration [J].
Brummer, RJM ;
Geerling, BJ ;
Stockbrugger, RW .
DIGESTIVE DISEASES AND SCIENCES, 1997, 42 (10) :2132-2137
[8]   IS THERE AN OPTIMAL DEGREE OF ACID SUPPRESSION FOR HEALING OF DUODENAL-ULCERS - A MODEL OF THE RELATIONSHIP BETWEEN ULCER HEALING AND ACID SUPPRESSION [J].
BURGET, DW ;
CHIVERTON, SG ;
HUNT, RH .
GASTROENTEROLOGY, 1990, 99 (02) :345-351
[9]   Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion [J].
Dammann, HG ;
Burkhardt, F .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1999, 11 (11) :1277-1282
[10]   Lansoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion [J].
Dammann, HG ;
Fuchs, W ;
Richter, G ;
Burkhardt, F ;
Wolf, N ;
Walter, TA .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (02) :359-364